Angus (688581): 24Q1 profit exceeded expectations and is optimistic about high overseas growth
Donghai Securities released a research report on April 24 stating that it gave Angus (688581.SH) a buy rating. The main reasons for the rating include: 1) performance growth exceeding expectations; 2) accelerated expansion of domestic and foreign markets;
Angus (688581) Company Brief Review Report: Performance Exceeds Expectations, Domestic and International Markets Work Together
Huafu Securities released a research report on April 22 stating that it gave Angus (688581.SH) a purchase rating, and the target price was 125.50 yuan. The main reasons for the rating include: 1) the company released its 2023 annual report and 2024 quarte
Angus Medical (688581): High domestic and foreign revenue growth, profits continue to improve
Angus (688581): High growth and release of new products at home and abroad can be expected
Angus (688581): Domestic and foreign sales expand simultaneously, profit margins continue to increase
Angus (688581) first coverage: rich product line with rookies in the field of digestive tract
Angus (688581) Company Review: Annual Results Forecast Released, Domestic and Overseas Product Coverage Increased Rapidly
Angus (688581): When leading domestic companies in the field of digestive consumables are growing rapidly
Angus (688581) Investment Value Analysis Report: Domestic endoscopic equipment advantage companies are pursuing steady and far-reaching internal and external training
Angus (688581): Performance is in line with expectations, domestic and foreign performance continues to rise
Angers (688581): Domestic and overseas combined revenue continues to grow, profit side performance is better
Angeles (688581): Domestic sales increased significantly in the third quarter, and net interest rate continued to rise
Angus (688581): Excellent endoscopic equipment company with comprehensive product line, dual engine drive development at home and abroad
Angers (688581): Domestic and international performance is growing at a steady pace and future growth rate can be expected
Angeles (688581): Recovery after the epidemic was good, overseas sales performance was outstanding
Angeles (688581): Rapid growth in performance, high equity incentive targets
Angus (688581): Excellent export performance boosts development confidence as incentives
Angus (688581): High performance growth equity incentives show confidence in growth
No Data